Sign in
Taking people in South KoreaNo phase

Testing a desensitization method during chemotherapy for gynecologic cancers

Tests immune tolerance induction during early chemotherapy in people with gynecologic cancer.

Key facts

Who runs it
Seoul National University Hospital
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Status
Recruiting
People taking part
1,000 people, planned
Started
21 May 2025
Expected to end
31 May 2028
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Proactive immune tolerance induction
  • Standard Treatment
  • Paclitaxel and carboplatin
  • Standard premedication (20 mg)
  • Reduced premedication (10 mg)
  • Reduced premedication (5 mg)
Record updated
7 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with a gynecologic cancer who are getting paclitaxel and carboplatin chemotherapy and have never had an allergic reaction to these drugs.

Age
19 years or older
Sex
Women only
Disease stage
Gynecologic cancer (ovarian, endometrial or cervical) treated with paclitaxel and carboplatin chemotherapy
Earlier treatment
No earlier hypersensitivity (allergic-type) reaction to paclitaxel or carboplatin

Main reasons for not taking part

  • Does not want to take part voluntarily
  • Unsuitable for the trial in the investigator's opinion

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies
  • Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin
  • Patients who are able to read and voluntarily provide written informed consent
  • Aged 19 years or older

Who cannot take part

  • Patients who do not wish to participate in this study voluntarily
  • Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial

Where in South Korea

  • Seoul National University HospitalSeoul, South KoreaContact: Hye-Ryun Kang, MD, PhDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer.

Read full original descriptionShow less

The main questions it aims to answer are:

- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles?

Participants will:

* Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.

The 6 groups in the trial

  • (Trial 1) Proactive immune tolerance induction with 20 mg dexamethasone as premedicationTreatment being tested

    Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 20 mg of dexamethasone.

    Treatment: Proactive immune tolerance induction, Paclitaxel and carboplatin, and Standard premedication (20 mg)

  • (Trial 1) Standard treatment (placebo) with 20 mg dexamethasone as premedicationExisting treatment, for comparison

    Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.

    Treatment: Standard Treatment, Paclitaxel and carboplatin, and Standard premedication (20 mg)

  • (Trial 2) Proactive immune tolerance induction with 10 mg dexamethasone as premedicationTreatment being tested

    Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 10 mg of dexamethasone.

    Treatment: Proactive immune tolerance induction, Paclitaxel and carboplatin, and Reduced premedication (10 mg)

  • (Trial 2) Standard treatment (placebo) with 20 mg dexamethasone as premedicationExisting treatment, for comparison

    Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.

    Treatment: Standard Treatment, Paclitaxel and carboplatin, and Standard premedication (20 mg)

  • (Trial 3) Proactive immune tolerance induction with 5 mg dexamethasone as premedicationTreatment being tested

    Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 5 mg of dexamethasone.

    Treatment: Proactive immune tolerance induction, Paclitaxel and carboplatin, and Reduced premedication (5 mg)

  • (Trial 3) Standard treatment (placebo) with 20 mg dexamethasone as premedicationExisting treatment, for comparison

    Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.

    Treatment: Standard Treatment, Paclitaxel and carboplatin, and Standard premedication (20 mg)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-controlled, Parallel-group, Open-label Trial to Evaluate the Efficacy of Proactive Immune Tolerance Induction to Paclitaxel and Carboplatin in Patients With Gynecologic Cancer
Plain-language title
Testing a desensitization method during chemotherapy for gynecologic cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 October 2026